Taysha Gene Therapies, Inc.TSHAEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 9.99% | 23.1M | — | 2024-11-14 |
| NOS. OF ABOVE PERSONS | 9.99% | 21.5M | flat | 2024-11-14 |
| RTW Investments, LP | 9.80% | 18.5M | — | 2024-02-14 |
| FMR LLC | 9.11% | 18.7M | ▼ -2.89pp | 2024-11-12 |
| BlackRock, Inc. | 6.60% | 13.5M | flat | 2024-11-08 |
| Venrock Healthcare Capital Partners III, L.P. | 4.40% | 9.0M | ▼ -1.20pp | 2024-11-14 |
| Astellas Pharma Inc. | 3.89% | 7.3M | — | 2023-08-18 |
| TCG Crossover GP I, LLC | 1.60% | 2.9M | ▼ -4.30pp | 2024-02-09 |
Insider Transactions
Net 90d: −$899.5K · buys $0 / sells $899.5KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-10 | Sukumar Nagendran | President and Head of R&D | Option exercise | 19.0K | $1.71 | $32.5K |
| 2026-04-10 | Sukumar Nagendran | President and Head of R&D | Sell (open market) | 200.0K | $4.46 | $892.0K |
| 2026-02-04 | Kamran Alam | CHIEF FINANCIAL OFFICER | Sell (open market) | 1.7K | $4.52 | $7.5K |
1–3 of 3